Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 4.85
UTHR's Cash-to-Debt is ranked lower than
62% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. UTHR: 4.85 )
Ranked among companies with meaningful Cash-to-Debt only.
UTHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 13.63 Max: 15951.56
Current: 4.85
0.69
15951.56
Equity-to-Asset 0.80
UTHR's Equity-to-Asset is ranked higher than
68% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. UTHR: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
UTHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.73 Max: 0.97
Current: 0.8
0.37
0.97
Debt-to-Equity 0.10
UTHR's Debt-to-Equity is ranked higher than
72% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. UTHR: 0.10 )
Ranked among companies with meaningful Debt-to-Equity only.
UTHR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.14 Max: 1.54
Current: 0.1
0
1.54
Debt-to-EBITDA 0.24
UTHR's Debt-to-EBITDA is ranked higher than
83% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. UTHR: 0.24 )
Ranked among companies with meaningful Debt-to-EBITDA only.
UTHR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.47  Med: 0.5 Max: 5.82
Current: 0.24
-3.47
5.82
Interest Coverage 80.21
UTHR's Interest Coverage is ranked lower than
74% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 80.21 )
Ranked among companies with meaningful Interest Coverage only.
UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 25.34 Max: 272.23
Current: 80.21
2.02
272.23
Piotroski F-Score: 5
Altman Z-Score: 8.29
Beneish M-Score: -2.08
WACC vs ROIC
9.84%
54.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 56.57
UTHR's Operating Margin % is ranked higher than
97% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. UTHR: 56.57 )
Ranked among companies with meaningful Operating Margin % only.
UTHR' s Operating Margin % Range Over the Past 10 Years
Min: -29.15  Med: 42.29 Max: 66.41
Current: 56.57
-29.15
66.41
Net Margin % 40.87
UTHR's Net Margin % is ranked higher than
95% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. UTHR: 40.87 )
Ranked among companies with meaningful Net Margin % only.
UTHR' s Net Margin % Range Over the Past 10 Years
Min: -17.52  Med: 25.31 Max: 44.64
Current: 40.87
-17.52
44.64
ROE % 32.46
UTHR's ROE % is ranked higher than
97% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. UTHR: 32.46 )
Ranked among companies with meaningful ROE % only.
UTHR' s ROE % Range Over the Past 10 Years
Min: -11.59  Med: 22.31 Max: 45.48
Current: 32.46
-11.59
45.48
ROA % 24.12
UTHR's ROA % is ranked higher than
97% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. UTHR: 24.12 )
Ranked among companies with meaningful ROA % only.
UTHR' s ROA % Range Over the Past 10 Years
Min: -6.75  Med: 15.42 Max: 32.03
Current: 24.12
-6.75
32.03
ROC (Joel Greenblatt) % 168.60
UTHR's ROC (Joel Greenblatt) % is ranked higher than
96% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. UTHR: 168.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
UTHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -43.92  Med: 102.64 Max: 215.37
Current: 168.6
-43.92
215.37
3-Year Revenue Growth Rate 17.40
UTHR's 3-Year Revenue Growth Rate is ranked higher than
74% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. UTHR: 17.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
UTHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 17.4  Med: 37.7 Max: 260.9
Current: 17.4
17.4
260.9
3-Year EBITDA Growth Rate 19.30
UTHR's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. UTHR: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
UTHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 19.3 Max: 128
Current: 19.3
0
128
3-Year EPS without NRI Growth Rate 14.00
UTHR's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. UTHR: 14.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
UTHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14 Max: 153.6
Current: 14
0
153.6
GuruFocus has detected 2 Warning Signs with United Therapeutics Corp UTHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» UTHR's 30-Y Financials

Financials (Next Earnings Date: 2018-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

UTHR Guru Trades in Q3 2017

Paul Tudor Jones 7,777 sh (New)
Jim Simons 1,273,000 sh (+51.98%)
Ray Dalio 92,770 sh (+25.42%)
David Dreman 3,466 sh (unchged)
Jeremy Grantham 2,400 sh (unchged)
Caxton Associates Sold Out
Lee Ainslie Sold Out
John Hussman 25,000 sh (-0.99%)
Joel Greenblatt 181,185 sh (-6.60%)
Ken Fisher 2,649 sh (-16.41%)
» More
Q4 2017

UTHR Guru Trades in Q4 2017

Charles Brandes 13,713 sh (New)
Pioneer Investments 15,066 sh (New)
Steven Cohen 191,999 sh (New)
Jim Simons 1,462,378 sh (+14.88%)
Ray Dalio 93,723 sh (+1.03%)
Jeremy Grantham 2,400 sh (unchged)
Ken Fisher 2,649 sh (unchged)
David Dreman 3,466 sh (unchged)
Paul Tudor Jones 4,085 sh (-47.47%)
John Hussman 10,000 sh (-60.00%)
Joel Greenblatt 66,270 sh (-63.42%)
» More
Q1 2018

UTHR Guru Trades in Q1 2018

Jeremy Grantham 6,000 sh (+150.00%)
Charles Brandes 26,930 sh (+96.38%)
Ray Dalio 161,349 sh (+72.16%)
Joel Greenblatt 81,760 sh (+23.37%)
Jim Simons 1,533,878 sh (+4.89%)
Steven Cohen 40,700 sh (unchged)
David Dreman 3,466 sh (unchged)
Ken Fisher Sold Out
John Hussman Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 15,054 sh (-0.08%)
Steven Cohen 4,112 sh (-97.86%)
» More
Q2 2018

UTHR Guru Trades in Q2 2018

Paul Tudor Jones 10,706 sh (New)
Pioneer Investments 24,742 sh (+64.35%)
Charles Brandes 29,775 sh (+10.56%)
Jeremy Grantham 6,200 sh (+3.33%)
Jim Simons 1,556,200 sh (+1.46%)
Joel Greenblatt 67,241 sh (-17.76%)
Steven Cohen 2,776 sh (-32.49%)
Ray Dalio 45,325 sh (-71.91%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-06-30 Reduce -17.76%0.02%$101.14 - $118.31 $ 125.5114%67,241
Charles Brandes 2018-06-30 Add 10.56%0.01%$101.14 - $118.31 $ 125.5114%29,775
Joel Greenblatt 2018-03-31 Add 23.37%0.02%$107.21 - $151.94 $ 125.51-1%81,760
Charles Brandes 2018-03-31 Add 96.38%0.03%$107.21 - $151.94 $ 125.51-1%26,930
Ken Fisher 2018-03-31 Sold Out $107.21 - $151.94 $ 125.51-1%0
Joel Greenblatt 2017-12-31 Reduce -63.42%0.2%$118.58 - $151.28 $ 125.51-1%66,270
Charles Brandes 2017-12-31 New Buy0.04%$118.58 - $151.28 $ 125.51-1%13,713
Joel Greenblatt 2017-09-30 Reduce -6.60%0.02%$114.6 - $136.81 $ 125.51-2%181,185
Ken Fisher 2017-09-30 Reduce -16.41%$114.6 - $136.81 $ 125.51-2%2,649
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:300347, XAMS:GLPG, TSE:4587, NAS:AGIO, XKRX:128940, NAS:SRPT, SZSE:002007, XBRU:ABLX, SZSE:000661, SHSE:603233, XKRX:215600, HKSE:01530, NAS:FGEN, NAS:IONS, NAS:LOXO, OSTO:SOBI, NAS:TECH, LSE:BTG, HKSE:00570, HKSE:01548 » details
Traded in other countries:UTH.Germany,
Headquarter Location:USA
United Therapeutics Corp is engaged in the healthcare sector. Its core offering includes pharmaceutical products to address unmet medical needs of patients.

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The firm is a market leader in two of the three primary drugs classes used to treat PAH. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug.

Ratios

vs
industry
vs
history
PE Ratio 7.70
UTHR's PE Ratio is ranked higher than
89% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. UTHR: 7.70 )
Ranked among companies with meaningful PE Ratio only.
UTHR' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 15.05 Max: 171.34
Current: 7.7
4.95
171.34
Forward PE Ratio 12.36
UTHR's Forward PE Ratio is ranked higher than
94% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. UTHR: 12.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 7.70
UTHR's PE Ratio without NRI is ranked higher than
90% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. UTHR: 7.70 )
Ranked among companies with meaningful PE Ratio without NRI only.
UTHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.95  Med: 15.05 Max: 171.34
Current: 7.7
4.95
171.34
Price-to-Owner-Earnings 7.03
UTHR's Price-to-Owner-Earnings is ranked higher than
88% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. UTHR: 7.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UTHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.08  Med: 19.51 Max: 577.3
Current: 7.03
5.08
577.3
PB Ratio 2.09
UTHR's PB Ratio is ranked higher than
73% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. UTHR: 2.09 )
Ranked among companies with meaningful PB Ratio only.
UTHR' s PB Ratio Range Over the Past 10 Years
Min: 1.8  Med: 3.4 Max: 10.39
Current: 2.09
1.8
10.39
PS Ratio 3.15
UTHR's PS Ratio is ranked higher than
82% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 3.15 )
Ranked among companies with meaningful PS Ratio only.
UTHR' s PS Ratio Range Over the Past 10 Years
Min: 2.61  Med: 4.67 Max: 11.47
Current: 3.15
2.61
11.47
Price-to-Free-Cash-Flow 11.29
UTHR's Price-to-Free-Cash-Flow is ranked higher than
86% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. UTHR: 11.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UTHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.84  Med: 16.1 Max: 644.84
Current: 11.29
7.84
644.84
Price-to-Operating-Cash-Flow 8.77
UTHR's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. UTHR: 8.77 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UTHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.13  Med: 13.06 Max: 46
Current: 8.77
7.13
46
EV-to-EBIT 4.53
UTHR's EV-to-EBIT is ranked higher than
82% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. UTHR: 4.53 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 7.3 Max: 127.2
Current: 4.53
-31.2
127.2
EV-to-EBITDA 4.40
UTHR's EV-to-EBITDA is ranked higher than
83% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. UTHR: 4.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 6.9 Max: 122.8
Current: 4.4
-33.7
122.8
EV-to-Revenue 2.57
UTHR's EV-to-Revenue is ranked higher than
86% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. UTHR: 2.57 )
Ranked among companies with meaningful EV-to-Revenue only.
UTHR' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 4.2 Max: 11.8
Current: 2.57
2
11.8
PEG Ratio 0.29
UTHR's PEG Ratio is ranked higher than
95% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. UTHR: 0.29 )
Ranked among companies with meaningful PEG Ratio only.
UTHR' s PEG Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.36 Max: 2.42
Current: 0.29
0.16
2.42
Shiller PE Ratio 17.97
UTHR's Shiller PE Ratio is ranked higher than
85% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. UTHR: 17.97 )
Ranked among companies with meaningful Shiller PE Ratio only.
UTHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.33  Med: 43.85 Max: 679.13
Current: 17.97
15.33
679.13
Current Ratio 4.64
UTHR's Current Ratio is ranked higher than
52% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. UTHR: 4.64 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.78 Max: 64.22
Current: 4.64
0.96
64.22
Quick Ratio 4.35
UTHR's Quick Ratio is ranked higher than
52% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. UTHR: 4.35 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 4.56 Max: 64.22
Current: 4.35
0.9
64.22
Days Inventory 210.03
UTHR's Days Inventory is ranked lower than
74% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. UTHR: 210.03 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 455.12
Current: 210.03
118.32
455.12
Days Sales Outstanding 52.60
UTHR's Days Sales Outstanding is ranked higher than
62% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. UTHR: 52.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 46.22 Max: 62.85
Current: 52.6
36.71
62.85
Days Payable 419.58
UTHR's Days Payable is ranked higher than
92% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. UTHR: 419.58 )
Ranked among companies with meaningful Days Payable only.
UTHR' s Days Payable Range Over the Past 10 Years
Min: 18.67  Med: 40.17 Max: 419.58
Current: 419.58
18.67
419.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.80
UTHR's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. UTHR: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UTHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.9  Med: -0.3 Max: 5.2
Current: 2.8
-9.9
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.89
UTHR's Price-to-Net-Cash is ranked lower than
61% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. UTHR: 9.89 )
Ranked among companies with meaningful Price-to-Net-Cash only.
UTHR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.29 Max: 1343.29
Current: 9.89
1.51
1343.29
Price-to-Net-Current-Asset-Value 5.67
UTHR's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. UTHR: 5.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
UTHR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.46  Med: 9.59 Max: 5533
Current: 5.67
1.46
5533
Price-to-Tangible-Book 2.15
UTHR's Price-to-Tangible-Book is ranked higher than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. UTHR: 2.15 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UTHR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 3.49 Max: 18.16
Current: 2.15
1.16
18.16
Price-to-Intrinsic-Value-Projected-FCF 0.68
UTHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. UTHR: 0.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UTHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.9 Max: 232.67
Current: 0.68
0.62
232.67
Price-to-Median-PS-Value 0.68
UTHR's Price-to-Median-PS-Value is ranked higher than
67% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. UTHR: 0.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UTHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.61  Med: 1.62 Max: 353.45
Current: 0.68
0.61
353.45
Price-to-Peter-Lynch-Fair-Value 0.31
UTHR's Price-to-Peter-Lynch-Fair-Value is ranked higher than
97% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. UTHR: 0.31 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UTHR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.91 Max: 5.82
Current: 0.31
0.21
5.82
Price-to-Graham-Number 0.86
UTHR's Price-to-Graham-Number is ranked higher than
88% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. UTHR: 0.86 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UTHR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.77  Med: 2.28 Max: 6.14
Current: 0.86
0.77
6.14
Earnings Yield (Greenblatt) % 22.24
UTHR's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. UTHR: 22.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UTHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6.2  Med: 10.05 Max: 40.2
Current: 22.24
-6.2
40.2
Forward Rate of Return (Yacktman) % 27.49
UTHR's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. UTHR: 27.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UTHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 2.8 Max: 28.7
Current: 27.49
-1.4
28.7

More Statistics

Revenue (TTM) (Mil) $1,743.90
EPS (TTM) $ 16.30
Beta1.15
Volatility29.47%
52-Week Range $100.57 - 152.55
Shares Outstanding (Mil)43.56

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 1,515 1,236 1,145 1,272
EBIT (Mil $) 723 502 371
EBITDA (Mil $) 752 530 402
EPS ($) 13.87 9.02 7.05 5.19
EPS without NRI ($) 13.87 9.02 7.05 5.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-9.06%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}